



ASX:M7T Twitter:@Mach7Tech

## Disclaimer 'Forward-Looking' Statements

Summary of information: This presentation contains general and background information about Mach7 Technologies Limited ("M7T") activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision. This presentation is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or under any other law. The presentation does not purport to contain all the information that a prospective investor may require in assessing a possible investment in M7T nor does it contain all the information which would be required in a prospectus prepared in accordance with the requirements of the Corporations Act 2001 (Cth). The information provided is in summary form, has not been independently verified, and should not be considered to be comprehensive or complete. It should be read solely in conjunction with the oral briefing provided by M7T and all other documents provided to you by M7T. The information in this presentation remains subject to change without notice. M7T is not responsible for providing updated information and assumes no responsibility to do so.

Not financial product advice: This financial information provided in this presentation is for information purposes only. The information contained in this presentation is of a general nature only and is not a financial product, investment advice or a recommendation to acquire M7T securities and has been prepared without taking into account the objectives, financial situation or needs of any person or entity. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. M7T is not licensed to provide financial product advice in respect of its securities or and other financial products. Cooling off rights do not apply to the acquisition of M7T securities. M7T assumes that the recipient is capable of making its own independent assessment, without reliance on this document, of the information and potential investment and will conduct its own investigation.

Disclaimer: M7T and its related bodies corporate and each of their respective directors, agents, officers, employees and advisors expressly disclaim, to the maximum extent permitted by the law, all abilities (however, caused, including negligence) in respect of, make no representations regarding, and take no responsibility for, any part of this presentation and make no representation or warranty as to the currency, accuracy, reliability or completeness of any information, statements, opinions, conclusions or representations contained in this presentation. In particular, this presentation does not constitute, and shall not be relied upon as, a promise, representation, warranty or guarantee as to the past, present or future performance of M7T.

Future performance: This presentation contains certain forward-looking statements and opinions. The forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements, including projections, forecasts and estimates, are provided as a general guide only and should not be relied on as an indication or guarantee of future performance and involve known and unknown risks, uncertainties and other factors, many of which are outside the control of M7T. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast.

Risks: An investment in M7T securities is subject to investment and other known and unknown risks, some of which are beyond the control of M7T. You should have regard to the 'Key Risks' section of this presentation which outlines some of these risks.

Not an offer: This presentation is not, and should not be considered as, an offer or an invitation to acquire securities in M7T or any other financial products and neither this document nor any of its contents will form the basis of any contract or commitment. This presentation is not a prospectus. Offers of securities in M7T will only be made in places which, or to persons to whom it would be lawful to make such offers. This presentation must not be disclosed to any other party and does not carry any right of publication. Neither this presentation nor any of its contents may be reproduced or used for any other purpose without the prior written consent of M7T.

No distribution in the US: This presentation is not an offer of securities for sale in the United States. Any securities to be issued by M7T have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act") and may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act. No public offer of the securities is being made in the United States and the information contained herein does not constitute an offer of securities for sale in the United States. This presentation is not for distribution directly or indirectly in or into the United States or to US persons.

Monetary values: Unless otherwise stated, all dollar values are in Australian dollars (AUD\$). The information in this presentation remains subject to change without notice.

Sophisticated and professional investor: By attending this presentation, you present and warrant that (i) if you are in Australia, you are a person to whom an offer of securities may be made without a disclosure document as defined in the Corporation Act 2001 (Cth) ("Corporation Act")) on the basis that you are exempt from the disclosure requirements of Part 6D.2 in accordance with Section 708(8) or 708(11) of the Corporations Act; (ii) if you are in the United States, you are a qualified institutional buyer (as defined under Rule 144A Under the U.S. Securities Act; (iii) if you are outside Australia and the United States, you are a person to whom an offer and issue of securities can be made outside Australia without registration, lodgement or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. If you are not such a person, you are not entitled to attend this presentation. Please return this presentation and any copies and do not provide this presentation to any other person.

No distribution: Distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable security laws.



## Cloud SaaS Healthcare IT Solutions Provider

- Providing enterprise software solutions to hospitals and clinics
- Growing global customer base, in the USA, UK, Qatar, China, South East Asia






## The Delivery of Healthcare




- 1 HOSPITAL
- 1 HEALTH RECORD


NOT THE PROBLEM NOR REALITY TODAY





Mach7 connects healthcare providers, aggregates medical records, and provides access to users through various clinical applications.





- OUTPATIENT CLINIC
- COMMUNITY HOSPITAL
- IMAGING CENTER
- LABORATORY





## Focused on the Challenges

Upwards of 75% of clinical data lives outside of the hospital's electronic medical record (EMR).



#### PROVIDER COLLABORATION

25% of U.S. patients reported that results and records from one provider did not reach another provider in time for their appointment.



#### INTEROPERABILITY

20% of malpractice claims involve missed or delayed diagnosis due to the deficits in communications between providers.



### **COORDINATION OF CARE**

80% of all serious medical errors involve miscommunication during care transitions.



#### CONNECTING HEALTH RECORDS

3 out of every 10 tests are reordered because results cannot be found.





### Mach7 Solutions Portfolio



Enterprise Solutions



Diagnostic Solutions



Connected Health Solutions



Artificial Intelligence Solutions

Powered by Mach7 Platform







## Solutions for Radiologists

Gain **one hour of efficiencies** daily with hanging protocols that work



#### **MODALITY**

Through intelligent modality workflow connectors:

- Provide DICOM Modality Worklist
- · Automate image distribution
- · Localize study metadata
- · Translate modality formats

10% – 20% cost reduction operating a modern PACS vs. traditional PACS offerings



### TECHNOLOGIST, AND RADIOGRAPHERS

Through a zero install Web-based client:


- Enable quality control (QC) workflows
- · Split and merge studies
- · Resolve study mismatches
- Verify studies



# SPECIALIST – RADIOLOGIST, CARDIOLOGIST

Powered by a smart worklist and diagnostic viewer:


- · Intelligently distribute workload
- Accurately prioritize STAT procedures
- · Enable hanging protocols to work consistently
- · Appropriately identify relevant clinical data
- · Simplify collaboration with colleagues
- Manage interruptions and communications with referring physicians and technologists
- Utilize Al to assist with diagnosis








### Solutions for Clinicians







### Diagnostic Workflow



### Mach7 Analytics Studio

Data platform and tools for adopting Al technologies and optimizing operations today.



## **Enabling Al Assisted Diagnosis**

- Mach7 uniquely positioned to take advantage of Al
- Transforming patient care with the power of Al
- Our Open Standards Data Platform provides access to images and reports
- Today, we are enabling Assisted Diagnosis in workflows
- Developing AI tools to improve Operational efficiency
- We provide clinical connectors to ecosystem of Al Algorithms



## Mach7 Customer Examples



- Academic medical center
- Enterprise Imaging
  Platform
- Client since **2014**



- Academic medical center, 130 sites
- Communications
  Workflow Engine
- Client since **2012**





- Partners Healthcare System
- Academic medical centers
- Client since **2010**



- 1 of 10 largest US hospital systems
- 30+ hospitals & clinics
- Client since **2015**

University of Vermont

- Academic medical center serving the State of Vermont
- Client since **2017**



- Hospital system serving VA & NC
- 12+ hospitals & clinics
- Client since **2014**



## Mach7 Customer Examples



- Qatar's leading hospital system
- 12 + hospitals
- Client since 2009

### **HCA**

- US & UK provider
- CommunicationWorkflow Engine& Image sharing
- Client since **2013**

### MaineHealth

- Statewide healthcare provider system
- 30+ hospitals and clinics
- Client since 2016



- Radiology service provider
- Enterprise Imaging Platform
- Client since **2014**



- 443-bed acute care hospital
- Enterprise Imaging
  Platform
- Client since 2018


### **Montefiore**

- 11 hospital health system in greater NYC
- Enterprise Imaging
  Platform
- Client since 2010



## Hospital Authority of Hong Kong 🎧





- Estimated deal value HK\$81 Million (~ A\$15M) over 5 years
- Enterprise Imaging and Viewer for entire Hong Kong territory
  - The Hospital Authority manages 43 public hospitals and institutions, 48 specialist outpatient clinics and 73 general outpatient clinics.

### • Objective:

 Reduce complexities and costs related to system integration and the consolidation, sharing, access and management of medical imaging data across Hong Kong.



### Sentara Healthcare





- Leading hospital system in Virginia & NC, USA
- 12 hospitals, 1000 + Physicians, 3800 provider staff
- Multiple PACS systems (GE, Agfa, Fuji, Medstream Cardiology, etc)

### Sentara Enterprise Imaging & Migration Projects

- Mach7 VNA and 20 million study migration underway.
- Started in 2014 as VNA contract of A\$2.6M grown to A\$9M / 10-year value deal.
- Awarded Vendor of Choice PACS Modernization
  - Perpetual subscription
  - Value to be communicated upon final contracting


### Objectives

 Reduce complexities and costs related to system integration and the consolidation, sharing, access and management of medical imaging data across all 'ologies'



## Mach7 is in a Healthy, Growing Market

### Expanded Market Available to Mach7 Platform



- In the last 15 months, Mach7 has increased its addressable market significantly.
- Market has shifted to Enterprise Imaging Solution and Mach7 technology is at the sweet spot.
- Healthcare customers need to reduce cost and improve efficiencies.
- PACS modernization with Enterprise Imaging is a must to gain efficiencies.
- Connected Health and Al Solutions are quickly becoming additional markets for us.
- Mach7 is ready for this paradigm shift.



## Industry Recognition

2016 IDC Marketscape Report Recognizes Mach7 Highest Overall in Capabilities and Strategies



Mach7 recognized for its patient-centric clinical platform with proven interoperability and functional flexibility.

The Mach7 platform is designed with an Application Independent Clinical Archive (AICA) architecture - allowing providers to manage access to disparate types of unstructured content among multiple clinical specialties, across the entire integrated clinical delivery network.





## Mach7 Technologies (M7T:AX)



2012

MACH7 PRODUCT LAUNCHED

2016

LISTED M7T:ASX

2018

FY18 REVENUE A\$8.6m

59 BLUE CHIP CUSTOMERS

RECURRING REVENUE A\$5.3m

STRONG SALES PIPELINE > \$100m

#### FINANCIAL INFORMATION (\$A)

Share price (5-Nov-18)	\$0.235
Number of shares (m) <sup>1</sup>	132.5m
Market Capitalisation	\$31.1m
Cash (30-Sep-18)	\$1.8m
Debt (30-Sep-18)	nil
Enterprise Value	\$29.3m

Excludes 15.62m unlisted performance rights & options



CARR excludes HAHK & Sentara recent wins – both of which will add to these values



## Mach7 Board and Leadership Team

**3OARD** 



Damien Lim NON-EXECUTIVE CHAIRMAN

- 21+ years experience in private equity and investment banking
- Co-founder of BioVeda Capital
- Currently serves on a number of boards and advisory committees



Eliot Siegel, MD NON-EXECUTIVE DIRECTOR

- Thought leader in the world of radiology and imaging informatics.
   Professor and Vice Chair at the University of Maryland School of Medicine
- Chief of Radiology & Nuc Med for the Veterans Affairs Maryland Healthcare System

**IANAGEMENT** 



- Formerly Americas Region CEO HCIT & CEO Enterprise Imaging & Care Area solutions at GE Healthcare
- Former President of Healthcare IT for Carestream Health



**Jenni Pilcher** CFO, Company Secretary

- Executive experience in ASX-listed healthcare companies
- Former CFO of Alchemia, and CFO and Co-Sec of Mesoblast (ASX:MSB)
- Part of global finance teams at Cadbury Schweppes and Medeva . PLC



Eric Rice CTO

- 20 years of systems architecture and design, engineering and management experience
- Held leadership roles and designed solutions for GE Healthcare



David Chambers NON-EXECUTIVE DIRECTOR

- 30+ years' extensive experience in HCIT and Life Science industry.
- Former CEO of Promedicus & Visage Imaging
- Currently Managing Director, Asia-Pacific, of Allscripts Healthcare Solutions



Wayne Spittle NON-EXECUTIVE DIRECTOR

- Extensive industry experience in the global healthcare
- Currently: consultant at Samsung Medison; Advisor at Novum Waves
- Former Executive VP with Samsung Medison and Health and Medical Equipment division



Ravi Krishnan FOUNDER, CSO

- Founding partner of Mach7 Technologies
- Nearly 20 years of experience with technology intricacies that drive medical imaging
- Previously worked at GE Healthcare and Agfa Healthcare




Mike Lampron

- 20+ years experience in business and operational management for HCIT companies
- Mike is responsible for our customers' success while driving excellence



## Strategy to Build Value






## Investment Highlights: Why Mach7? Why Now?



#### **Sales Growth**

- Pipeline +50% (last 15 months)
- Growing global customer base across healthcare tiers



## Expanding Addressable Market to ~\$4B

- Engagement of distributors and value-added resellers
- Entry into new markets



#### **Product Innovation**

- Data Services Platform
- Diagnostic PACS Solution
- Cloud offerings
- Artificial Intelligence
- New release Version 11.8



### **Enhanced Leadership**

 Restructured Board of Directors, adding worldrenowned radiologist and A.I. enthusiast, and experienced CEO from PACS and EMR industry



